Core Viewpoint - The new national basic medical insurance drug list has officially been implemented, significantly improving the accessibility of innovative therapies for lymphoma treatment, including bispecific antibodies and ADCs [1][4]. Group 1: Impact of New Drug Inclusion - The inclusion of innovative drugs like Gefitinib and Vobasertib in the national medical insurance directory enhances patient accessibility and treatment options for lymphoma [4]. - The new insurance policy allows for comprehensive coverage of core innovative drugs throughout the treatment process for lymphoma, thereby increasing the availability of these therapies [1][4]. Group 2: Patient Needs and Treatment Efficacy - Lymphoma is a common malignant tumor in China, with diffuse large B-cell lymphoma (DLBCL) accounting for approximately 40% of cases, and 30%-40% of patients facing recurrence or refractory conditions [2]. - There is a pressing demand for new drugs among patients with DLBCL, as highlighted in the "2022 White Paper on the Survival Status of DLBCL Patients in China" [3]. Group 3: Historical Context and Improvements - Since the approval of the first targeted CD20 therapy, Rituximab, in 1998, the five-year survival rate for DLBCL patients in China has improved by 10%-15% [5]. - The continuous introduction of innovative drugs into the medical insurance system has led to significant improvements in treatment efficacy and quality of life for lymphoma patients [5]. Group 4: Recommendations for Policy Implementation - Experts emphasize the importance of ensuring that innovative therapies reach patients effectively, advocating for consistent core rules and standards in medical insurance policies across regions [5]. - There is a call for innovative payment methods and a multi-tiered insurance system to facilitate the rapid adoption of new therapies, particularly for difficult-to-treat or relapsed lymphoma patients [5].

Core Insights - The implementation of the 2025 National Basic Medical Insurance Drug List on January 1, 2026, includes innovative drugs for lymphoma, particularly bispecific antibody drugs, marking a significant advancement in the treatment landscape for lymphoma patients [1][3]. Group 1: Lymphoma Treatment Landscape - The incidence of lymphoma is rising due to improved diagnostic capabilities and an aging population, with approximately 100,000 new cases reported annually in China [3]. - The five-year survival rate for lymphoma patients in China is about 40%, which lags behind that of Western countries, partly due to limited access to innovative drugs [3]. - The establishment of specialized lymphoma centers is being promoted nationwide to enhance diagnostic precision and treatment outcomes [3]. Group 2: Innovative Drug Developments - Recent advancements in lymphoma treatment include the emergence of monoclonal antibodies, bispecific antibodies, antibody-drug conjugates (ADCs), and small molecule targeted therapies [3]. - The introduction of the new medical insurance policy is expected to accelerate the integration of innovative drugs into clinical practice, aligning China's treatment standards more closely with international benchmarks [3]. Group 3: Specific Drug Insights - Among various lymphoma subtypes, diffuse large B-cell lymphoma (DLBCL) is the most prevalent, accounting for about 50% of hospitalized patients in specialized centers [4]. - Approximately 30%-40% of DLBCL patients may progress to relapsed or refractory disease, which poses significant treatment challenges and increases healthcare costs [4]. - The bispecific antibody drug, Gefitinib, is now included in the National Basic Medical Insurance Drug List, providing new treatment options for patients with relapsed/refractory DLBCL [4][5]. Group 4: Financial Impact of Insurance Coverage - The inclusion of innovative drugs in the insurance list significantly reduces treatment costs; for instance, the ADC drug, Vebotuzumab, saw an 80% reduction in treatment expenses after being added to the insurance list [8]. - Patients previously deterred by high costs can now access innovative treatments, improving their chances of survival [8]. Group 5: Regional Healthcare Initiatives - The establishment of regional medical alliances aims to ensure that advanced treatments are accessible locally, promoting the goal of providing high-quality care without the need for patients to travel far [9]. - The 2025 National Medical Insurance Drug List added 114 new drugs, with 50 being innovative drugs, particularly benefiting the oncology sector [9].

Group 1 - The report highlights that the ADC (Antibody-Drug Conjugate) market is experiencing rapid growth, with the global market size surpassing $14 billion and expected to exceed $66 billion by 2030, reflecting a CAGR of 30.3% [2][19][26] - In China, the ADC market is also developing rapidly, projected to exceed 60 billion RMB by 2030, driven by increasing clinical demand and government support [2][26][30] - The report emphasizes the rigid clinical demand for ADCs, particularly in treating breast cancer and lymphoma, with over 2.4 million new cases globally each year, indicating a clear trend towards replacing traditional chemotherapy [2][19] Group 2 - The report outlines that multiple ADC products have been included in China's medical insurance directory for 2024, marking a significant step in the commercialization of ADCs in the country [11][15] - The Chinese government has implemented various policies to accelerate the development and commercialization of ADCs, including guidelines from the National Medical Products Administration [9][10][11] - The report notes that the domestic ADC industry has formed a complete industrial chain, with upstream and midstream companies poised to benefit significantly from this growth [27][28]

Core Viewpoint - The recent reforms in medical insurance payment methods, particularly the special single negotiation mechanism, aim to support the use of innovative drugs and medical devices, addressing concerns about high costs in medical institutions [1][3][4]. Group 1: Special Single Negotiation Mechanism - The special single negotiation mechanism is designed to provide reasonable compensation for medical services when the costs exceed three times the payment standard [2][4]. - The mechanism will be refined in conjunction with national policies supporting the development of innovative drugs and medical devices, indicating a commitment to support medical institutions in treating complex and critical patients [3][4]. - The number of cases eligible for special single negotiation should not exceed 5% of the total discharged cases under the DRG or DIP payment systems [4]. Group 2: Impact on Innovative Drugs - The reforms are expected to benefit drugs listed in the commercial health insurance innovative drug directory, particularly those with high clinical value and patient benefits [5][6]. - The introduction of the commercial health insurance innovative drug directory is anticipated to provide a framework for local authorities to evaluate and implement the special single negotiation policy effectively [5][7]. - Local governments, such as those in Hainan and Guangzhou, are developing their own innovative drug directories to enhance the support for innovative drugs and medical devices [8][9]. Group 3: Regional Initiatives - Regions with relatively abundant medical insurance funds, like Shanghai and Zhejiang, have already launched local supportive directories for innovative drugs and devices [8][10]. - The Zhejiang Medical Security Bureau has established a list of innovative medical technologies eligible for payment incentives, focusing on drugs that have recently entered the basic medical insurance directory [11][12]. - Shanghai has implemented a strategy to adjust payment standards for cases involving new technologies, allowing for full payment without a control ratio for high-cost cases [12].

Investment Rating - The report maintains a strong rating for the pharmaceutical and biotechnology sector, indicating it is expected to outperform the market [6]. Core Insights - The report highlights the breakthrough therapy of TRS005, an ADC targeting CD20, which shows potential to outperform existing treatments for DLBCL [4][40]. - The DLBCL market is projected to grow significantly, with the Chinese market expected to increase from RMB 58 billion in 2019 to RMB 186 billion by 2024, and further to RMB 369 billion by 2030, reflecting a CAGR of 26.2% [21][24]. - The report emphasizes the importance of innovative drugs and suggests focusing on companies with strong performance and potential catalysts in the upcoming quarters [4][5]. Summary by Sections 1. Market Review - The CITIC Pharmaceutical Index rose by 1.5% during the week of June 23-27, 2025, underperforming the CSI 300 Index by 0.5 percentage points [3][49]. - The top five performing stocks included Shenzhou Cell (+30.5%), Haooubo (+27.1%), and Huaren Health (+26.0%) [3][63]. 2. DLBCL and ADC Treatment - DLBCL accounts for approximately 30-40% of all NHL cases, with a significant portion of patients remaining untreated despite existing therapies [4][17]. - The report discusses the transition from traditional chemotherapy to targeted therapies, highlighting the introduction of ADCs as a promising treatment avenue [24][27]. - TRS005 has shown promising results in early trials, with an overall response rate (ORR) of 59.4% in the 1.8 mg/kg dosage group [42][46]. 3. Investment Recommendations - The report suggests a focus on innovative drugs as a long-term investment strategy, particularly in companies that are expected to report strong Q2 earnings [4][5]. - Recommended stocks include Innovent Biologics, Kintor Pharmaceutical, and Zhenbao Island, among others [5][13]. 4. Industry Trends - The report notes that the ADC sector is gaining traction, with TRS005 being a key focus due to its potential advantages over existing therapies [40][47]. - The overall pharmaceutical sector is experiencing a shift towards innovative treatments, driven by advancements in technology and an aging population [21][24].